Wellington Management Group LLP Makes New $1.61 Million Investment in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Wellington Management Group LLP purchased a new stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 100,613 shares of the company's stock, valued at approximately $1,609,000. Wellington Management Group LLP owned about 0.09% of Centessa Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. HighMark Wealth Management LLC bought a new stake in Centessa Pharmaceuticals during the second quarter valued at approximately $840,000. TD Asset Management Inc lifted its holdings in shares of Centessa Pharmaceuticals by 40.5% during the 2nd quarter. TD Asset Management Inc now owns 321,168 shares of the company's stock worth $2,900,000 after acquiring an additional 92,524 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Centessa Pharmaceuticals by 1.3% during the 2nd quarter. American Century Companies Inc. now owns 935,151 shares of the company's stock worth $8,444,000 after acquiring an additional 12,031 shares during the last quarter. XTX Topco Ltd purchased a new position in Centessa Pharmaceuticals in the second quarter worth $148,000. Finally, Farallon Capital Management LLC increased its stake in Centessa Pharmaceuticals by 438.0% in the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company's stock valued at $18,024,000 after acquiring an additional 1,625,000 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company's stock.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, CEO Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $18.46, for a total transaction of $1,615,176.16. Following the sale, the chief executive officer now owns 575,661 shares of the company's stock, valued at approximately $10,626,702.06. The trade was a 13.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CTO Tia L. Bush sold 17,813 shares of the stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $18.00, for a total transaction of $320,634.00. Following the completion of the transaction, the chief technology officer now directly owns 147,615 shares of the company's stock, valued at approximately $2,657,070. The trade was a 10.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 374,642 shares of company stock valued at $6,375,876 in the last 90 days. Insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Trading Up 6.3 %

Shares of Centessa Pharmaceuticals stock traded up $1.04 on Thursday, hitting $17.55. The stock had a trading volume of 579,714 shares, compared to its average volume of 432,806. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a one year low of $6.65 and a one year high of $18.97. The stock's 50-day simple moving average is $16.62 and its two-hundred day simple moving average is $13.51. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of -11.47 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.05. As a group, sell-side analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Guggenheim lifted their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a "buy" rating in a research note on Friday, November 15th. Jefferies Financial Group boosted their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, September 11th. BMO Capital Markets increased their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a research report on Monday, September 16th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Finally, B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a "buy" rating and a $33.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.